menu

Our news

HomeOur news
HomeOur news

Our company news

  • ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression b

    ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression b

    posted in Our news by myrcludex.admin

    ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression b

    ...

    read the rest

    13 04, 19
  • MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.

    MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.

    posted in Our news by myrcludex.admin

    MYR Pharmaceuticals today announced that the final results of the MYR203 study of bulevirtide (Myrcludex), MYR´s first-in-class entry inhibitor for treatment of hepatitis B and D infection, will be presented at the General Session of the upcoming 2019 ILC meeting in Vienna

    ...

    read the rest

    04 04, 19
  • MYR Pharmaceuticals Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D Infections

    MYR Pharmaceuticals Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D Infections

    posted in Our news by myrcludex.admin

    MYR Pharmaceuticals announced today that the British Medicines and Healthcare products Regulatory Agency (MHRA) has issued the Promising Innovative Medicine (PIM) designation for MYR’s lead compound Bulevirtide (Myrcludex). The designation is granted in the indication of chronic hepatitis delta virus (HDV) infection.

    ...

    read the rest

    07 03, 19
  • MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta at the AASLD Meeting in San Francisco

    MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta at the AASLD Meeting in San Francisco

    posted in Our news by myrcludex.admin

    BAD HOMBURG, Germany, October 29, 2018 / PRNewswire / -- MYR Pharma today announced that the results of 48 weeks of administration of Myrcludex, MYR`s first-in-class entry inhibitor for treatment of hepatitis B and D infection, will be presented at the Presidential Plenary Session of the upcoming meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco:

    ...

    read the rest

    29 10, 18
  • Pages